We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.18 | 4.13% | 29.74 | 29.63 | 28.415 | 28.47 | 46,987,483 | 00:59:17 |
From May 2019 to May 2024
By Cecilia Butini
BioNTech SE and Pfizer Inc. said Monday that they have received approval from the German regulatory authority to commence the phase 2/3 trial in Germany for their Covid-19 vaccine.
The two pharmaceutical companies said their vaccine candidate, identified as BNT162b2, is being tested for safety and efficacy in a placebo-controlled trial with up to 30,000 participants globally, including in Germany. The trial for the vaccine--which isn't yet approved for distribution anywhere in the world--will be conducted in about 120 sites worldwide, the companies said.
Pfizer and BioNTech are expecting to get regulatory review for the vaccine as early as October 2020. If regulatory approval is obtained, they plan to be able to supply up to 100 million vaccine doses globally by the end of 2020 and roughly 1.3 billion by the end of 2021, they said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
September 07, 2020 10:07 ET (14:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
